Download presentation
Presentation is loading. Please wait.
1
HBV Management in 2012… Where Are We Heading?
2
Management of Chronic Hepatitis B
4
Unanswered Questions from the REVEAL
5
27 Year Follow-up on Maori population in New Zealand with Genotype D
6
9 Year Natural History Study of CHB Patients in the United States
7
Independent Factors Associated with Disease Progression and HCC
9
Patients Who Developed Serious Liver-related Complicationsa May Be Excluded from Treatment by Current Guidelines/Algorithms
10
Evaluate CHB Patients for Treatment
11
Liver Biopsy for Treatment Candidate Selection
12
Fibro Test: Indeterminate rates ~ 50%
13
FibroScan®
14
Evaluation on Patients in the Gray Zone
15
Recommendations for First-Line Therapy in Patients Without Cirrhosis
17
Change in Ishak Scores at Year 3-7 of Entecavir Therapy by Baseline Fibrosis Score
19
Suboptimal Response to Entecavir Therapy
22
Change in Ishak Scores at Year 5 of Tenofovir Therapy by Baseline Fibrosis Score
23
No Patient with Persistent Viremia During Year 5 Analysis for Tenofovir Therapy
24
Combining ETV and TDF vs. ETV Therapy
25
HBsAg Loss in HBeAg-Positive and HBeAg-Negative Patients
26
Phase I/II Study of a Potent HBsAg Release Inhibitor: REP 9AC
27
REP 9AC Study Results
28
Immunophrophylaxis failure rates of the infants born to mothers with different virologic features
29
Lamivudine Therapy for the Prevention of Vertical Transmission During Pregnancy
31
Elective Cesareans Delivery and Risk of Perinatal Transmission of HBV
33
Where Are We Heading?
34
Thank You!
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.